Clinical trial
Combination of Alemtuzumab (Anti-CD52) and Rituximab (Anti-CD20) at Low-doses in Chronic Graft Versus Host Disease Treatment After First-line Therapy Failure.
NCT01042509 is registered in ClinicalTrials.gov with Hospital Universitario Dr. Jose E. Gonzalez as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination of Alemtuzumab (Anti-CD52) and Rituximab (Anti-CD20) at Low-doses in Chronic Graft Versus Host Disease Treatment After First-line Therapy Failure.
- Lead sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- January 31, 2012
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.